The Phase I/II Clinical Trial of Bevacizumab for Treatment of Ophthalmic Diseases Completed

Essex Bio-Technology Ltd announced that a Phase I/II clinical trial of EB12-20145P, a recombinant anti-VEGF humanised monoclonal antibody injection jointly developed by the Group and Shanghai Henlius Biotech, Inc., has been completed in patients with wet age-related macular degeneration. The results of this study demonstrated the good safety and tolerability of EB12-20145P.